Charles Rudin

Charles Rudin is the world's leading authority on the molecular biology of small cell lung cancer, having defined the four transcriptional subtypes of SCLC (ASCL1-high, NEUROD1-high, YAP1-high, POU2F3-high) that underpin the disease's heterogeneity. He pioneered DLL3 as a therapeutic target and led clinical development of rovalpituzumab tesirine. His comprehensive genomic analyses have revealed the neuroendocrine differentiation spectrum in SCLC and mechanisms of chemotherapy and immunotherapy resistance. He co-chairs the SCLC Consortium and has led MSK's SCLC precision medicine program.